Comorbidities prolonged viral shedding of patients infected with SARS-CoV-2 omicron variant in Shanghai: A multi-center, retrospective, observational study

被引:8
作者
Pei, Lei [1 ]
Chen, Ying [1 ]
Zheng, Xiangtao [1 ]
Gong, Fangchen [1 ]
Liu, Wenbin [1 ]
Lin, Jingsheng [2 ]
Zheng, Ruizhi [3 ]
Yang, Zhitao [1 ]
Bi, Yufang [3 ]
Chen, Erzhen [1 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Emergency, Ruijin 2 Rd, Shanghai 200025, Peoples R China
[2] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Disciplinary Dev & Planning, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Endocrine & Metab Dis, Shanghai, Peoples R China
关键词
COVID-19; SARS-CoV-2; Omicron; Comorbidity; Viral shedding time;
D O I
10.1016/j.jiph.2022.12.003
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: As the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) surges amid the coronavirus disease 2019 (COVID-19) pandemic, there is limited comorbidities data associated with viral shedding time (VST). We aimed to investigate the effect of comorbidities on VST in asymptomatic and mild patients with omicron. Methods: A multi-center, retrospective, observational study was conducted from March 12, 2022 to May 24, 2022 in Shanghai. The analysis was adjusted for patients' baseline demographic, using log-rank test and logistic regression model. Results: The study enrolled 198,262 subjects. The median duration of viral shedding time (VST) was 8.29 days. The number of cumulative viral shedding events was significantly lower in the chronic obstructive pulmonary disease (COPD), hyperlipidemia, diabetes, urinary system disease, and cardiocerebrovascular disease than in the no corresponding comorbidities group. Patients with comorbidities had a lower incidence of viral shedding, and the most significant independent risk factor is COPD (aOR 1.78, 95% CI: 1.53-2.08, p < 0.001). Across different age ranges, the comorbidities affecting viral shedding also differ, with the greatest risk factors for viral shedding being hyperlipidemia (aOR 2.23, 95% CI: 1.50-3.31, p < 0.001) and COPD (aOR 1.85, 95% CI: 1.50-2.28, p < 0.001) between ages of 18-39 and 40-64, and thyroid dysfunction (aOR 2.36, 95% CI: 1.60-3.47, p < 0.001) above age 64. Conclusions: Omicron-infected patients with comorbidities might prolong the VST. The independent risk factors also differ across age ranges, suggesting that providing targeted effective prevention and control guidance and allocating appropriate resources to different populations should be a crucial strategy. (c) 2022 Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:182 / 189
页数:8
相关论文
共 23 条
  • [1] Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa
    Abdullah, F.
    Myers, J.
    Basu, D.
    Tintinger, G.
    Ueckermann, V
    Mathebula, M.
    Ramlall, R.
    Spoor, S.
    de Villiers, T.
    Van der Walt, Z.
    Cloete, J.
    Soma-Pillay, P.
    Rheeder, P.
    Paruk, F.
    Engelbrecht, A.
    Lalloo, V
    Myburg, M.
    Kistan, J.
    van Hougenhouck-Tulleken, W.
    Boswell, M. T.
    Gray, G.
    Welch, R.
    Blumberg, L.
    Jassat, W.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 116 : 38 - 42
  • [2] Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
    Cele, Sandile
    Jackson, Laurelle
    Khoury, David S.
    Khan, Khadija
    Moyo-Gwete, Thandeka
    Tegally, Houriiyah
    San, James Emmanuel
    Cromer, Deborah
    Scheepers, Cathrine
    Amoako, Daniel G.
    Karim, Farina
    Bernstein, Mallory
    Lustig, Gila
    Archary, Derseree
    Smith, Muneerah
    Ganga, Yashica
    Jule, Zesuliwe
    Reedoy, Kajal
    Hwa, Shi-Hsia
    Giandhari, Jennifer
    Blackburn, Jonathan M.
    Gosnell, Bernadett, I
    Karim, Salim S. Abdool
    Hanekom, Willem
    von Gottberg, Anne
    Bhiman, Jinal N.
    Lessells, Richard J.
    Moosa, Mahomed-Yunus S.
    Davenport, Miles P.
    de Oliveira, Tulio
    Moore, Penny L.
    Sigal, Alex
    [J]. NATURE, 2022, 602 (7898) : 654 - +
  • [3] Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
    Collie, Shirley
    Champion, Jared
    Moultrie, Harry
    Bekker, Linda-Gail
    Gray, Glenda
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (05) : 494 - 496
  • [4] Winter of Omicron-The Evolving COVID-19 Pandemic
    del Rio, Carlos
    Omer, Saad B.
    Malani, Preeti N.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (04): : 319 - 320
  • [5] Interrelations between COVID-19 and other disorders
    Gasmi, Amin
    Peana, Massimiliano
    Pivina, Lyudmila
    Srinath, Shvetha
    Benahmed, Asma Gasmi
    Semenova, Yuliya
    Menzel, Alain
    Dadar, Maryam
    Bjorklund, Geir
    [J]. CLINICAL IMMUNOLOGY, 2021, 224
  • [6] SARS-CoV-2 variants, spike mutations and immune escape
    Harvey, William T.
    Carabelli, Alessandro M.
    Jackson, Ben
    Gupta, Ravindra K.
    Thomson, Emma C.
    Harrison, Ewan M.
    Ludden, Catherine
    Reeve, Richard
    Rambaut, Andrew
    Peacock, Sharon J.
    Robertson, David L.
    [J]. NATURE REVIEWS MICROBIOLOGY, 2021, 19 (07) : 409 - 424
  • [7] SARS-COV-2 Variants: Differences and Potential of Immune Evasion
    Hirabara, Sandro M.
    Serdan, Tamires D. A.
    Gorjao, Renata
    Masi, Laureane N.
    Pithon-Curi, Tania C.
    Covas, Dimas T.
    Curi, Rui
    Durigon, Edison L.
    [J]. FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 11
  • [8] Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities- surveillance results from southern Sweden, July 2021 to January 2022
    Kahn, Fredrik
    Bonander, Carl
    Moghaddassi, Mahnaz
    Rasmussen, Magnus
    Malmqvist, Ulf
    Inghammar, Malin
    Bjork, Jonas
    [J]. EUROSURVEILLANCE, 2022, 27 (09)
  • [9] Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies
    Kannan, Saathvik R.
    Spratt, Austin N.
    Sharma, Kalicharan
    Chand, Hitendra S.
    Byrareddy, Siddappa N.
    Singh, Kamal
    [J]. JOURNAL OF AUTOIMMUNITY, 2022, 126
  • [10] Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California
    Lewnard, Joseph A.
    Hong, Vennis X.
    Patel, Manish M.
    Kahn, Rebecca
    Lipsitch, Marc
    Tartof, Sara Y.
    [J]. NATURE MEDICINE, 2022, 28 (09) : 1933 - +